IRVINE, Calif., Oct. 21, 2025 /PRNewswire/ — Breakthrough Genomics, a leader in AI-powered clinical genomics interpretation, today announced new research highlights and product updates presented at the American Society of Human Genetics (ASHG) Annual Meeting, held October 15–18 in Boston. The company showcased its largest interpreted literature database to date and shared results from its Virtual Geneticist® platform, which uses large language models (LLMs) for literature curation, automated ACMG classification, and clinical report generation.
Dr. Laura Li, CEO of Breakthrough Genomics, delivered a presentation during the ASHG Lightning Talk Session, “Scaling Genomic Medicine: From Patient-Centered Tools to Population and Therapeutic Insights.” Dr. Li detailed how Virtual Geneticist® LLM models can help geneticists and researchers to get trustworthy, up-to-date literature evidence at their fingertips. “Virtual Geneticist® LLM interprets the literature and automates ACMG/ClinGen based genetic variant classification so clinical labs can move from hours of manual review to minutes of confident decision-making – while preserving expert oversight.”
Breakthrough Genomics is leading the way in AI for genomics
About Breakthrough Genomics
Breakthrough Genomics delivers Virtual Geneticist®, an AI-powered clinical interpretation platform that transforms complex genomic data into clear, evidence-backed insights. Built for hospital and reference-lab environments, Virtual Geneticist® supports end-to-end workflows – from genomic data ingestion and QC to ACMG classification and report drafting – and can be deployed on-premises or in a cloud. Our mission is to help labs and geneticists move from hours of manual review to minutes of confident decision-making, improving outcomes for patients and families worldwide. Learn more at https://btgenomics.com/our-technology/ and connect with us on https://www.linkedin.com/company/btgenomics/.
Media Contact
press@btgenomics.com
Breakthrough Genomics
SOURCE Breakthrough Genomics
NORTHAMPTON, MA / ACCESS Newswire / December 26, 2025 / Specialized nutrition experts are key…
"Despite clear congressional mandates and FDA authorization, the Drug Enforcement Administration failed to act within…
WASHINGTON, Dec. 26, 2025 /PRNewswire/ -- Over the past decade, China has evolved from a biotechnology…
SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a…
While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn…
DALLAS, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and…